Women's Cancer Research Program

女性癌症研究计划

• 批准号: 9099674
• 负责人: Michael B Kastan
• 金额: $ 3.64万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9099674
• 关键词: Address; Area; Biological Markers; Biology; Cancer Center Support Grant; Cancer Patient; Cancer Research Project; Characteristics; Clinical; Clinical Trials; Communities; Development; Disease; Endocrine; Environment; Estrogen receptor positive; Fostering; Funding; Genetic Heterogeneity; Goals; Growth; Intervention; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of thyroid; Nature; Neoplasms; Outcome; Paper; Pathway interactions; Patient Care; Program Development; Publishing; Reporting; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resistance; Scientist; Subgroup; Therapeutic; Therapeutic Intervention; Translating; Translational Research; Treatment Protocols; Ursidae Family; Validation; Woman; cancer subtypes; clinically actionable; experience; inflammatory breast cancer; innovation; insight; malignant breast neoplasm; member; novel therapeutic intervention; organizational structure; programs; therapeutic target; translational approach; triple-negative invasive breast carcinoma; tumor

ABSTRACT A tremendous amount of progress has been made in identifying the pathways of pathological importance in cancer and in the validation of steps in these pathways as therapeutic targets. However, the genetic heterogeneity among cancers, and the utilization by different tumor types of different growth and survival pathways has made it difficult to realize the therapeutic potential of even the most tractable targets. Addressing this impediment to progress is a central theme of the research being undertaken by members of the Women's Cancer Program where the development of therapeutic strategies that are tailored to specific cancer subtypes is a primary focus. These efforts have led to the identification of targets the inhibition of which are likely to selectively impact triple negative breast cancer, endocrine resistant ER-positive breast cancers, Inflammatory breast cancer, thyroid cancer, and gynecologic cancers. This successful strategy will be continued in the next funding period with efforts being directed towards (a) the definition of pathways of pathological importance in different women's cancers the exploitation of which will yield new strategies for therapeutic intervention, (b) identification and validation of biomarkers which will help to define specific disease characteristics and/or report on the efficacy of treatment regimens, and (c) development of and accrual to innovative clinical trials that build upon the scientific expertise of the program members. These initiatives will be facilitated by the existing infrastructure of the program and by the new opportunities for interaction that are contemplated. The collective experience of 30 primary and 15 secondary program members from across 12 different departments will be brought to bear on these research questions and these initiatives will be supported by a significant portfolio of research grants (~$14M cancer funding/year) that the program has amassed. The Women's Cancer Program is an exceptionally productive and interactive group of scientists having published 706 papers in the past funding period of which 203 were the product of inter-programmatic interactions.

抽象的 在确定病理重要性的途径中，已经取得了巨大进展 癌症和在这些途径中作为治疗靶标的步骤验证。但是，遗传 癌症之间的异质性，以及不同生长和生存的不同肿瘤类型的利用 途径使得甚至最容易实现目标的靶标的治疗潜力变得困难。 解决这一进步的障碍是研究成员正在进行的研究的中心主题 妇女癌症计划，该计划的制定是针对特定的量身定制的治疗策略 癌症亚型是主要重点。这些努力导致了目标的抑制 可能会选择性地影响三重阴性乳腺癌，抗内分泌阳性乳腺癌， 炎性乳腺癌，甲状腺癌和妇科癌症。这个成功的策略将是 继续在下一个资金期间继续努力（a）的定义 在不同妇女癌症中的病理重要性，其剥削将产生新的策略 治疗干预，（b）生物标志物的识别和验证，这将有助于定义特定疾病 有关治疗方案有效性的特征和/或报告，以及（c）开发和应计为 创新的临床试验基于计划成员的科学专业知识。这些举措将 该计划的现有基础设施和新的互动机会可以促进 考虑到。来自12个小学和15个二级计划成员的集体经验 在这些研究问题上将带来不同的部门，这些举措将是 在该计划拥有的大量研究补助金（约1400万美元的癌症资金）的支持下 积聚。妇女癌症计划是一个异常富有成效且互动的科学家组 在过去的资金期间发表了706篇论文，其中203是策略间的产物 互动。